This is a phase II, multicenter, randomized, double-blind, placebo- controlled trial of the safety, tolerability and efficacy of pain relief of lamotrigine for HIV-associated sensory neuropathy. Peripheral neuropathy is a common complication of HIV infection. HIV-associated sensory neuropathy is a common form of neuropathy in advanced HIV infection. Approximately 30% of patients with AIDS develop HIV-associated sensory neuropathy. Symptoms can be painful and can greatly impact on the activities of daily living as well as the quality of life. A direct viral etiology has been postulated as a causative agent. Certain antiretrovirals (ddI, ddC, d4T) are also known to cause neuropathy in this patient population. Therapeutic treatment of painful sensory neuropathy has been difficult. Current management involves the use of sympomatic or pain-modifying agents. Symptomatic relief with tricyclic antidepressants, non-steroidal anti-inflammatory agents, topical capsaicin or opiates has been limited. A trial is currently underway with a potentially restorative agent, nerve growth factor. Lamotrigine is a newly approved anti-convulsant which blocks voltage sensitive sodium channels, resulting in inhibition of glutamate and aspartate release. Lamotrigine has similar efficacy in maximal electro- shock models to carbamazepine and phenytoin, both of which have proven efficacious for the treatment of painful diabetic neuropathy. To date, there have only been anectodal reports of the efficacy of lamotrigine for treatment of HIV-associated sensory neuropathy.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Al-Sofiani, Mohammed E; Yanek, Lisa R; Faraday, Nauder et al. (2018) Diabetes and Platelet Response to Low-Dose Aspirin. J Clin Endocrinol Metab 103:4599-4608
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Aboud, Katherine S; Barquero, Laura A; Cutting, Laurie E (2018) Prefrontal mediation of the reading network predicts intervention response in dyslexia. Cortex 101:96-106
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Salemi, Parissa; Skalamera Olson, Julie M; Dickson, Lauren E et al. (2018) Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab 103:158-168
Robert Braši?, James; Mari, Zoltan; Lerner, Alicja et al. (2018) Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. Int J Phys Med Rehabil 6:
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866

Showing the most recent 10 out of 1014 publications